Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany

Oncotype DX was the only gene expression test that was estimated to reduce costs versus standard care in Germany. The reimbursement of Oncotype DX testing in standard clinical practice in Germany should be considered.